Biologic therapy for atopic asthma and beyond

Bosnjak, 2011, Treatment of allergic asthma: modulation of Th2 cells and their responses., Respir Res, 12, 114, 10.1186/1465-9921-12-114

Holgate, 2008, Treatment strategies for allergy and asthma., Nat Rev Immunol, 8, 218, 10.1038/nri2262

Lotvall, 2011, Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome., J Allergy Clin Immunol, 127, 355, 10.1016/j.jaci.2010.11.037

Kon, 1998, Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma., Lancet, 352, 1109, 10.1016/S0140-6736(97)12261-9

van den Hoogen, 2011, Use of monoclonal antibodies in renal transplantation., Immunotherapy, 3, 871, 10.2217/imt.11.72

Busse, 2008, Daclizumab Asthma Study GroupDaclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial., Am J Respir Crit Care Med, 178, 1002, 10.1164/rccm.200708-1200OC

Borish, 1999, Interleukin-4 receptor in moderate atopic asthma. A phase III randomized, placebo-controlled trial., Am J Respir Crit Care Med, 160, 1816, 10.1164/ajrccm.160.6.9808146

Borish, 2001, IL-4R Asthma Study GroupEfficacy of soluble IL-4 receptor for the treatment of adults with asthma., J Allergy Clin Immunol, 107, 963, 10.1067/mai.2001.115624

Wenzel, 2013, Dupilumab in persistent asthma with elevated eosinophil levels., N Engl J Med, 368, 2455, 10.1056/NEJMoa1304048

Hart, 2002, Preclinical efficacy and safety of pascolizumab (SB240683): a humanized antiinterleukin-4 antibody with therapeutic potential in asthma., Clin Exp Immunol, 130, 93, 10.1046/j.1365-2249.2002.01973.x

Gauvreau, 2011, Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma., Am J Respir Crit Care Med, 183, 1007, 10.1164/rccm.201008-1210OC

Kariyawasam, 2009, Effects of anti-IL-13 (Novartis QAX576) on inflammatory responses following nasal allergen challenge (NAC)., Am J Respir Crit Care Med, 179, A3642

Singh, 2010, A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma., BMC Pulm Med, 10, 3, 10.1186/1471-2466-10-3

May, 2012, Preclinical development of CAT-354, an IL-13-neutralising antibody, for the treatment of severe uncontrolled asthma., Br J Pharmacol, 166, 177, 10.1111/j.1476-5381.2011.01659.x

Piper, 2013, A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma., Eur Respir J, 41, 330, 10.1183/09031936.00223411

Corren, 2011, Lebrikizumab treatment in adults with asthma., N Engl J Med, 365, 1088, 10.1056/NEJMoa1106469

Kasaian, 2011, IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Ra2., J Immunol, 187, 561, 10.4049/jimmunol.1100467

Burmeister Getz, 2009, Human pharmacokineticspharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma., J Clin Pharmacol, 49, 1025, 10.1177/0091270009341183

Wenzel, 2007, Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies., Lancet, 370, 1422, 10.1016/S0140-6736(07)61600-6

Corren, 2010, A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma., Am J Respir Crit Care Med, 181, 788, 10.1164/rccm.200909-1448OC

Di Domenico, 2011, Xolair in asthma therapy: an overview., Inflamm Allergy Drug Targets, 10, 2, 10.2174/187152811794352042

Demeule, 2009, A therapeutic antibody and its antigen form different complexes in serum than in phosphate-buffered saline: a study by analytical ultracentrifugation., Anal Biochem, 388, 279, 10.1016/j.ab.2009.03.012

Beck, 2004, Omalizumab-induced reductions in mast cell Fce psilon RI expression and function., J Allergy Clin Immunol, 114, 527, 10.1016/j.jaci.2004.06.032

Schroeder, 2010, Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization., J Allergy Clin Immunol, 125, 896, 10.1016/j.jaci.2009.10.021

Domingo, 2011, Omalizumab in the management of oral corticosteroid-dependent IGE-mediated asthma patients., Curr Med Res Opin, 27, 45, 10.1185/03007995.2010.536208

Gevaert, 2013, Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma., J Allergy Clin Immunol, 131, 110, 10.1016/j.jaci.2012.07.047

Bousquet, 2007, Predicting and evaluating response to omalizumab in patients with severe allergic asthma., Respir Med, 101, 1483, 10.1016/j.rmed.2007.01.011

Humbert, 2009, Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis., Allergy, 64, 81, 10.1111/j.1398-9995.2008.01846.x

Zaidi, 2010, Regulation of Syk kinase and FcRbeta expression in human basophils during treatment with omalizumab., J Allergy Clin Immunol, 125, 902, 10.1016/j.jaci.2009.12.996

Schumann, 2012, Omalizumab in patients with severe asthma: the XCLUSIVE study., Clin Respir J, 6, 215, 10.1111/j.1752-699X.2011.00263.x

Hochhaus, 2003, Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma., Curr Med Res Opinion, 19, 491, 10.1185/030079903125002171

Brightbill, 2010, Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice., J Clin Invest, 120, 2218, 10.1172/JCI40141

Gauvreau, 2012, Effect of an anti-m1 prime monoclonal antibody, Memp1972a, in a phase II proof-of-activity allergen challenge study in patients with mild asthma., Am J Resp Crit Care Med, 185, A6793

Flood-Page, 2007, A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma., Am J Respir Crit Care Med, 176, 1062, 10.1164/rccm.200701-085OC

Flood-Page, 2003, Eosinophils role remains uncertain as antiinterleukin-5 only partially depletes numbers in asthmatic airway., Am J Respir Crit Care Med, 167, 199, 10.1164/rccm.200208-789OC

Leckie, 2000, Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response., Lancet, 356, 2144, 10.1016/S0140-6736(00)03496-6

Kay, 2003, Eosinophils and interleukin-5: the debate continues., Am J Respir Crit Care Med, 167, 1586, 10.1164/rccm.2304001

Menzies-Gow, 2003, Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics., J Allergy Clin Immunol, 111, 714, 10.1067/mai.2003.1382

Nair, 2009, Mepolizumab for prednisone-dependent asthma with sputum eosinophilia., N Engl J Med, 360, 985, 10.1056/NEJMoa0805435

Haldar, 2009, Mepolizumab and exacerbations of refractory eosinophilic asthma., N Engl J Med, 360, 973, 10.1056/NEJMoa0808991

Pavord, 2012, Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial., Lancet, 380, 651, 10.1016/S0140-6736(12)60988-X

Gevaert, 2011, Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis., J Allergy Clin Immunol, 128, 989, 10.1016/j.jaci.2011.07.056

Kips, 2003, Effect of SCH55700, a humanized antihuman interleukin-5 antibody, in severe persistent asthma: a pilot study., Am J Respir Crit Care Med, 167, 1655, 10.1164/rccm.200206-525OC

Castro, 2011, Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo controlled study., Am J Respir Crit Care Med, 184, 1125, 10.1164/rccm.201103-0396OC

Gevaert, 2006, Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps., J Allergy Clin Immunol, 118, 1133, 10.1016/j.jaci.2006.05.031

Kolbeck, 2010, MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function., J Allergy Clin Immunol, 125, 1344, 10.1016/j.jaci.2010.04.004

Busse, 2010, Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma., J Allergy Clin Immunol, 125, 1237, 10.1016/j.jaci.2010.04.005

Molfino, 2012, Reduction in the number and severity of exacerbations following acute severe asthma: results of a placebo-controlled, randomized clinical trial with benralizumab., Am J Respir Crit Care Med, 185, A2753

Kay, 2006, The role of T lymphocytes in asthma., Chem Immunol Allergy, 91, 59, 10.1159/000090230

Bellou, 2005, Costimulation: critical pathways in the immunologic regulation of asthma., Curr Allergy Asthma Rep, 5, 149, 10.1007/s11882-005-0089-6

Oh, 2010, Investigational therapeutics targeting the IL-4IL-13STAT-6 pathway for the treatment of asthma., Eur Respir Rev, 19, 46, 10.1183/09059180.00007609

Saggini, 2011, Allergic inflammation: role of cytokines with special emphasis on IL-4., Int J Immunopathol Pharmacol, 24, 305, 10.1177/039463201102400204

Hart, 1999, Differential responses of human monocytes and macrophages to IL-4 and IL-13., J Leukoc Biol, 66, 575, 10.1002/jlb.66.4.575

Hershey, 2003, IL-13 receptors and signaling pathways: an evolving web., J Allergy Clin Immunol, 111, 677, 10.1067/mai.2003.1333

Gould, 2008, IgE in allergy and asthma today., Nat Rev Immunol, 8, 205, 10.1038/nri2273

Amin, 2012, The role of mast cells in allergic inflammation., Respir Med, 106, 9, 10.1016/j.rmed.2011.09.007

Patou, 2008, Staphylococcus aureus enterotoxin B, protein A, and lipoteichoic acid stimulations in nasal polyps., J Allergy Clin Immunol, 121, 110, 10.1016/j.jaci.2007.08.059

Morjaria, 2009, Off-label use of omalizumab in nonasthma conditions: new opportunities., Expert Rev Resp Med, 3, 299, 10.1586/ers.09.11

Rothenberg, 2006, The eosinophil., Annu Rev Immunol, 24, 147, 10.1146/annurev.immunol.24.021605.090720

Wenzel, 1999, Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics., Am J Respir Crit Care Med, 160, 1001, 10.1164/ajrccm.160.3.9812110

Flood-Page, 2003, Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics., J Clin Invest, 112, 1029, 10.1172/JCI17974

Tanaka, 2004, Role of interleukin-5 and eosinophils in allergen-induced airway remodeling in mice., Am J Respir Cell Mol Biol, 31, 62, 10.1165/rcmb.2003-0305OC

Molfino, 2012, Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor., Clin Exp Allergy, 42, 712, 10.1111/j.1365-2222.2011.03854.x

Hamelmann, 1997, Antiinterleukin-5 antibody prevents airway hyperresponsiveness in a murine model of airway sensitization., Am J Respir Crit Care Med, 155, 819, 10.1164/ajrccm.155.3.9117011

Kung, 1995, Involvement of IL-5 in a murine model of allergic pulmonary inflammation: prophylactic and therapeutic effect of an anti-IL-5 antibody., Am J Respir Cell Mol Biol, 13, 360, 10.1165/ajrcmb.13.3.7654390

Mathur, 1999, TRFK-5 reverses established airway eosinophilia but not established hyperresponsiveness in a murine model of chronic asthma., Am J Respir Crit Care Med, 159, 580, 10.1164/ajrccm.159.2.9712018